Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin
Tetanus toxin (TeNT) is one of the most toxic proteins. Neutralizing antibodies against TeNT are effective in prevention and treatment. In this study, 14 anti-tetanus nanobodies were obtained from a phage display nanobody library by immunizing a camel with the C-terminal receptor-binding domain of T...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2366641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185608057585664 |
|---|---|
| author | Kexuan Cheng Jiansheng Lu Jiazheng Guo Rong Wang Lei Chen Xi Wang Yujia Jiang Yating Li Changyan Xu Qinglin Kang Gulisaina Qiaerxie Peng Du Chen Gao Yunzhou Yu Zhixin Yang Wei Wang |
| author_facet | Kexuan Cheng Jiansheng Lu Jiazheng Guo Rong Wang Lei Chen Xi Wang Yujia Jiang Yating Li Changyan Xu Qinglin Kang Gulisaina Qiaerxie Peng Du Chen Gao Yunzhou Yu Zhixin Yang Wei Wang |
| author_sort | Kexuan Cheng |
| collection | DOAJ |
| description | Tetanus toxin (TeNT) is one of the most toxic proteins. Neutralizing antibodies against TeNT are effective in prevention and treatment. In this study, 14 anti-tetanus nanobodies were obtained from a phage display nanobody library by immunizing a camel with the C-terminal receptor-binding domain of TeNT (TeNT-Hc) as the antigen. After fusion with the human Fc fragment, 11 chimeric heavy-chain antibodies demonstrated nanomolar binding toward TeNT-Hc. The results of toxin neutralization experiments showed that T83–7, T83–8, and T83–13 completely protected mice against 20 × the median lethal dose (LD50) at a low concentration. The neutralizing potency of T83–7, T83–8, and T83–13 against TeNT is 0.4 IU/mg, 0.4 IU/mg and 0.2 IU/mg, respectively. In the prophylactic setting, we found that 5 mg/kg of T83–13 provided the mice with full protection from tetanus, even when they were injected 14 days before exposure to 20 × LD50 TeNT. T83–7 and T83–8 were less effective, being fully protective only when challenged 7 or 10 days before exposure, respectively. In the therapeutic setting, 12 h after exposure to TeNT, 1 ~ 5 mg/kg of T83–7, and T83–8 could provide complete protection for mice against 5 × LD50 TeNT, while 1 mg/kg T83–13 could provide complete protection 24 h after exposure to 5 × LD50 TeNT. Our results suggested that these antibodies represent prophylactic and therapeutic activities against TeNT in a mouse model. The T83–7, T83–8, and T83–13 could form the basis for the subsequent development of drugs to treat TeNT toxicity. |
| format | Article |
| id | doaj-art-13b0ffc440814458b9e5816a3a74d3a7 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-13b0ffc440814458b9e5816a3a74d3a72025-08-20T02:16:40ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2366641Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxinKexuan Cheng0Jiansheng Lu1Jiazheng Guo2Rong Wang3Lei Chen4Xi Wang5Yujia Jiang6Yating Li7Changyan Xu8Qinglin Kang9Gulisaina Qiaerxie10Peng Du11Chen Gao12Yunzhou Yu13Zhixin Yang14Wei Wang15Department of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, ChinaDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, ChinaTetanus toxin (TeNT) is one of the most toxic proteins. Neutralizing antibodies against TeNT are effective in prevention and treatment. In this study, 14 anti-tetanus nanobodies were obtained from a phage display nanobody library by immunizing a camel with the C-terminal receptor-binding domain of TeNT (TeNT-Hc) as the antigen. After fusion with the human Fc fragment, 11 chimeric heavy-chain antibodies demonstrated nanomolar binding toward TeNT-Hc. The results of toxin neutralization experiments showed that T83–7, T83–8, and T83–13 completely protected mice against 20 × the median lethal dose (LD50) at a low concentration. The neutralizing potency of T83–7, T83–8, and T83–13 against TeNT is 0.4 IU/mg, 0.4 IU/mg and 0.2 IU/mg, respectively. In the prophylactic setting, we found that 5 mg/kg of T83–13 provided the mice with full protection from tetanus, even when they were injected 14 days before exposure to 20 × LD50 TeNT. T83–7 and T83–8 were less effective, being fully protective only when challenged 7 or 10 days before exposure, respectively. In the therapeutic setting, 12 h after exposure to TeNT, 1 ~ 5 mg/kg of T83–7, and T83–8 could provide complete protection for mice against 5 × LD50 TeNT, while 1 mg/kg T83–13 could provide complete protection 24 h after exposure to 5 × LD50 TeNT. Our results suggested that these antibodies represent prophylactic and therapeutic activities against TeNT in a mouse model. The T83–7, T83–8, and T83–13 could form the basis for the subsequent development of drugs to treat TeNT toxicity.https://www.tandfonline.com/doi/10.1080/21645515.2024.2366641Tetanus toxinnanobodyheavy chain antibodyneutralizing antibodyphage display library |
| spellingShingle | Kexuan Cheng Jiansheng Lu Jiazheng Guo Rong Wang Lei Chen Xi Wang Yujia Jiang Yating Li Changyan Xu Qinglin Kang Gulisaina Qiaerxie Peng Du Chen Gao Yunzhou Yu Zhixin Yang Wei Wang Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin Human Vaccines & Immunotherapeutics Tetanus toxin nanobody heavy chain antibody neutralizing antibody phage display library |
| title | Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin |
| title_full | Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin |
| title_fullStr | Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin |
| title_full_unstemmed | Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin |
| title_short | Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin |
| title_sort | characterization of neutralizing chimeric heavy chain antibodies against tetanus toxin |
| topic | Tetanus toxin nanobody heavy chain antibody neutralizing antibody phage display library |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2366641 |
| work_keys_str_mv | AT kexuancheng characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT jianshenglu characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT jiazhengguo characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT rongwang characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT leichen characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT xiwang characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT yujiajiang characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT yatingli characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT changyanxu characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT qinglinkang characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT gulisainaqiaerxie characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT pengdu characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT chengao characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT yunzhouyu characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT zhixinyang characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin AT weiwang characterizationofneutralizingchimericheavychainantibodiesagainsttetanustoxin |